PDS Biotechnology (PDSB) Expected to Announce Earnings on Wednesday

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) is expected to be releasing its Q1 2025 earnings data before the market opens on Wednesday, May 14th. Analysts expect PDS Biotechnology to post earnings of ($0.27) per share for the quarter.

PDS Biotechnology (NASDAQ:PDSB - Get Free Report) last released its quarterly earnings data on Thursday, March 27th. The company reported ($0.21) earnings per share for the quarter, topping analysts' consensus estimates of ($0.29) by $0.08. On average, analysts expect PDS Biotechnology to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

PDS Biotechnology Trading Down 2.4%

NASDAQ PDSB traded down $0.03 on Friday, reaching $1.19. 63,827 shares of the company were exchanged, compared to its average volume of 464,445. The business's fifty day moving average price is $1.19 and its 200 day moving average price is $1.67. The stock has a market capitalization of $54.41 million, a P/E ratio of -1.03 and a beta of 1.40. The company has a current ratio of 2.84, a quick ratio of 2.84 and a debt-to-equity ratio of 0.55. PDS Biotechnology has a fifty-two week low of $0.85 and a fifty-two week high of $4.42.

Analysts Set New Price Targets

Separately, HC Wainwright decreased their price objective on PDS Biotechnology from $21.00 to $13.00 and set a "buy" rating on the stock in a report on Thursday, March 27th.

PDS Biotechnology Company Profile

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.